

Does CT-derived fractional flow reserve help reduce healthcare costs and improve patient care in a real-world setting?

Submission date 22/06/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 29/07/2022	Overall study status Ongoing	<input checked="" type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/09/2025	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Coronary artery disease (CAD) remains the major cause of heart-related deaths and overall deaths in the United Kingdom. Angina is a symptom of chest pains that is a warning of the presence of CAD. In order to investigate patients with possible angina, doctors can perform a CT coronary angiogram (CTCA) that looks to identify CAD. Whilst CTCA is excellent at detecting CAD it cannot determine whether this is causing the patient's symptoms. A new technology, CT-derived fractional flow reserve (FFRCT), was introduced by NHS England in 2018 to help identify the patients with significant CAD that is causing angina. This study aims to look at the patients who had FFRCT and compare them to patients who didn't have this test to determine whether the new technology has been useful. The researchers will assess its impact on the length of the patient journey, the number of tests the patients required and whether there was any difference in heart attack and death rates.

Who can participate?

Patients aged 18 years and over who underwent a CTCA as part of an investigation for CAD between 2017 and 2020 at participating sites

What does the study involve?

A retrospective analysis of data captured from NHS digital's datasets.

What are the possible benefits and risks of participating?

There are no specific benefits to the participants involved as their care will have already occurred and this is a retrospective observational study. The benefits are establishing the potential benefit of this technology in the NHS.

Where is the study run from?

Liverpool Heart and Chest Hospital (UK)

When is the study starting and how long is it expected to run for?

January 2019 to December 2028

Who is funding the study?
Medical Research Council (UK)

Who is the main contact?
Dr Tim Fairbairn, Timothy.Fairbairn@lhch.nhs.uk

Contact information

Type(s)

Principal investigator

Contact name

Dr Tim Fairbairn

Contact details

Liverpool Heart and Chest Hospital
Thomas Drive
Liverpool
United Kingdom
L14 3PE
+44 (0)151 600 1477
timothy.fairbairn@lhch.nhs.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

285996

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 46652

Study information

Scientific Title

CT-derived fractional flow reserve in stable heart disease and coronary computed tomography angiography helps improve patient care and societal costs

Acronym

FISH and CHIPS

Study objectives

To determine whether a coronary computed tomography angiography (CCTA) and CT-derived fractional flow reserve (FFRCT) diagnostic pathway reduces health-related events, time to

diagnosis and overall healthcare costs compared to a 'standard of care' CCTA diagnostic chest pain pathway.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 24/02/2021, North West - Liverpool Central Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)2071048118, +44 (0)2071048035, +44 (0)2071048016; liverpoolcentral.rec@hra.nhs.uk), ref: 20/NW/0430

Study design

Pragmatic 'real world' multi-centre retrospective observational analytic cohort study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Cardiovascular disease

Interventions

Participants will include all individuals who had a CCTA performed at an institute participating in NHS England's Innovation and Technology Payment (ITP) programme during 2018-2020. All CCTA 12 months prior to and up to 24 months following the start of an FFRCT programme (total study period 36 months) will be assessed. The cohort from this population that received an FFRCT will be separately identified.

Patients will be followed up at 90 days, 12 months and a minimum of 24 months post CCTA for the pre-defined primary and secondary endpoints.

Intervention Type

Other

Primary outcome(s)

Collected from NHS digital's datasets for 90 days, 12 months and a minimum of 24 months follow-up post CCTA:

1. MI event rate, hospitalization for acute coronary syndrome, MI deaths and all-cause death
2. Downstream testing: numbers of non-invasive functional tests, and invasive coronary angiograms without revascularisation performed following the index FFRCT
3. Cost analysis: total cost to the NHS of the index test and all downstream investigations and hospital admissions

Key secondary outcome(s)

Collected from NHS digital's datasets for 90 days, 12 months and a minimum of 24 months follow-up post CCTA:

1. Time to diagnosis - trust referral to treatment (RTT) time
2. Qualitative assessment of the impact of the FFRCT health technology

Completion date

01/12/2028

Eligibility

Key inclusion criteria

1. Age \geq 18 years
2. CCTA for the assessment of coronary artery disease (CAD)

Participant type(s)

Patient, Population

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

102616

Key exclusion criteria

1. Age <18 years
2. Coronary artery calcium scoring alone
3. CCTA in addition to a second CT investigation for a non-coronary indication (CT transcatheter aortic valve implantation [TAVI], CT aorta)
4. Previous CCTA within 6 months
5. Prior coronary artery bypass graft (CABG)/myocardial infarction (MI)
6. Entry into a separate FFRCT research study during the study timeframe

Date of first enrolment

01/03/2022

Date of final enrolment

22/06/2022

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Liverpool Heart and Chest Hospital
Thomas Drive
Liverpool
United Kingdom
L14 3PE

Sponsor information

Organisation
Liverpool Heart and Chest Hospital

ROR
<https://ror.org/000849h34>

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
Participant-level data will not be shared as per the Data Access Request Service (DARS) agreement

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		04/04/2025	09/09/2025	Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	version 1	01/12/2020	30/06/2022	No	Yes
Protocol file	version 2	01/06/2022	30/06/2022	No	No
Statistical Analysis Plan			09/09/2025	No	No